Wistar Team Receives Prestigious Award from National Clinical Research Forum for DNA-based Zika Research

Wistar and partners at the Perelman School of Medicine, University of Pennsylvania; Inovio Pharmaceuticals; and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their...
19-Apr-2018 10:05 AM EDT Add to Favorites

Top HIV Cure Research Team Refutes Major Recent Results on How to Identify HIV Persistence

An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not...
18-Apr-2018 10:20 AM EDT Add to Favorites

Soluble Antibodies Play Immune Suppressive Role in Tumor Progression

Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models.
12-Apr-2018 2:05 PM EDT Add to Favorites

Novel Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors, according to study results published online in EMBO...
11-Apr-2018 2:05 PM EDT Add to Favorites

Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer

Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
27-Mar-2018 12:00 PM EDT Add to Favorites

Wistar and YourEncore Unite to Advance Life Sciences Opportunities

Wistar and YourEncore, Inc., a life sciences and consumer goods consulting company engaging highly experienced, top talent industry experts, have signed a Memorandum of Understanding (MoU) to help accelerate the advancement of Wistar's early-stage...
23-Mar-2018 1:05 PM EDT Add to Favorites

Targeting Telomeres to Overcome Therapy Resistance in Advanced Melanoma

A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma.
21-Mar-2018 10:10 AM EDT Add to Favorites

New Targeted Therapeutic Approach to Combat Ovarian Cancer

According to a new study by The Wistar Institute, EZH2 inhibitors that are currently in clinical development for hematological malignancies and solid tumors may be effectively targeted to epithelial ovarian cancers overexpressing the CARM1 protein.
9-Mar-2018 8:00 AM EST Add to Favorites

see all news